Deep Dive Into Apellis Pharmaceuticals Stock: Analyst Perspectives (18 Ratings)
Portfolio Pulse from Benzinga Insights
In the past three months, 18 analysts have provided diverse ratings for Apellis Pharmaceuticals (NASDAQ:APLS), with a consensus 12-month price target of $75.94, marking a 12.6% increase from the previous target. The ratings range from bullish to bearish, reflecting varied perspectives on the company's performance and outlook. Apellis Pharmaceuticals, a clinical-stage biopharmaceutical company, has shown significant revenue growth and strong profitability despite challenges in market capitalization, ROE, and ROA.
February 28, 2024 | 8:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Apellis Pharmaceuticals has received diverse analyst ratings with an updated average 12-month price target of $75.94, indicating a positive outlook based on its significant revenue growth and profitability metrics.
The consensus among analysts suggests a bullish outlook for Apellis Pharmaceuticals, with a significant upward revision in the 12-month price target. This optimism is supported by the company's impressive revenue growth rate and profitability metrics, despite some challenges in market capitalization, return on equity, and return on assets. The diverse range of analyst ratings and the upward trend in price targets indicate strong investor interest and potential for stock price appreciation in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100